The arrival of the first AI-discovered and AI-designed drug target at phase 3 proves the capability of algorithms to unlock therapeutic avenues that traditional research has failed to reach.
Article index:
- Historic milestone with first dose administered in phase 3
- Nature of pulmonary fibrosis and current treatment limitations
- Clinical trial design and positive phase 2 results
- Discovery of the TNIK protein and breaking traditional molds
- Academic journey and international regulatory approvals
- Insilico’s financial growth and final licensing timeline
- Frequently asked questions
Historic milestone with first dose administered in phase 3
Biotechnology company Insilico Medicine announced on Tuesday the administration of the first dose to the first patient for its innovative drug rentosertib in the Genesis-3 phase 3 clinical study, marking a milestone in modern medicine as the first drug compound whose biological target and molecular design were entirely discovered through generative AI algorithms to enter the final stage of human clinical trials.
The first dose was administered at the prestigious Peking Union Medical College Hospital in the Chinese capital, coinciding with Shanghai Pulmonary Hospital enrolling its first patient in the study on the same day, marking the culmination of years of scientific work integrating AI into pharmacology.
Nature of pulmonary fibrosis and current treatment limitations
Rentosertib acts as a small-molecule inhibitor of the TNIK protein and is being evaluated for its clinical efficacy in treating idiopathic pulmonary fibrosis, a chronic scarring lung disease affecting approximately 5 million patients worldwide, characterized by its severity with an average post-diagnosis life expectancy of just three to four years.
Currently approved international treatments for the disease are limited to slowing the rate of lung function decline while being completely unable to stop scarring or repair damaged tissue, making the creation of a new therapeutic pathway a genuine hope for saving the lives of millions of sufferers.
Clinical trial design and positive phase 2 results
The clinical trial is a randomized, double-blind, placebo-controlled study spanning 52 weeks and aiming to enroll 320 patients across 47 specialized medical centers in China. The primary success endpoint is measuring the annual rate of decline in forced vital capacity of the lungs, the gold standard criteria for global approval of pulmonary fibrosis drugs.
This phase builds upon impressive results achieved in phase 2a, where patients receiving a 60 mg daily dose showed significant improvement with an average lung capacity increase of 98.4 milliliters after 12 weeks, compared to a loss and decline of 20.3 milliliters in the placebo group.
Discovery of the TNIK protein and breaking traditional molds
The clinical study is led by Professor Zujian Xu from Peking Union Medical College Hospital, with prominent academic Nanshan Zhong and Dr. Zhang Chen from Shanghai Pulmonary Hospital participating as co-principal investigators. Professor Xu emphasized that the TNIK protein, discovered by AI as a disease target, “had never been associated with pulmonary fibrosis in the history of medical research prior to the intervention of algorithms.”
He added that this success proves beyond a doubt that AI is forging an independent scientific path that breaks traditional templates and patterns used in discovering therapeutic targets for intractable diseases.
Academic journey and international regulatory approvals
The journey of rentosertib has been documented in major peer-reviewed journals, with its discovery mechanism published in Nature Biotechnology in 2024, its phase 2 clinical results in Nature Medicine in 2025, and cell regeneration and biological aging resistance data in 2026.
The drug received Orphan Drug Designation from the U.S. Food and Drug Administration in February 2023, and Breakthrough Therapy Designation from China’s Center for Drug Evaluation in May 2025, granting it fast-track and exceptional approval pathways.
Insilico’s financial growth and final licensing timeline
This scientific success was accompanied by strong financial performance for Insilico, listed on the Hong Kong Stock Exchange since December 2025, announcing revenues of $106 million for the first half of 2026, a 287 percent year-over-year increase, achieving its first profitable half-year since its listing.
The company is also developing an inhaled formulation of the drug that underwent a phase 1 clinical trial in April 2026, and Professor Xu estimated that obtaining final commercial approval from phase 3 will take about three to four years if positive results continue.
Frequently asked questions
Question: What is rentosertib and what is its significance in modern medical history?
Answer: It is the first drug whose target and molecular design were entirely discovered by AI to reach phase 3 clinical trials.
Question: What disease does the innovative drug target and how many people are affected?
Answer: It targets idiopathic pulmonary fibrosis, a fatal respiratory disease affecting about 5 million people worldwide.
Question: What is the expected timeline for the drug to receive final commercial approval?
Answer: Medical estimates indicate that completing phase 3 and obtaining final licensing takes between 3 to 4 years.
